Innoviva (INVA) Deferred Taxes (2018 - 2026)
Innoviva posted quarterly Deferred Taxes of $41.0 million for Q1 2026, up 17199.17% year-on-year from N/an in Q1 2025, and up 907.81% on a QoQ basis from $4.1 million in Q3 2025.
Innoviva (INVA) has 9 years of Deferred Taxes data on file, last reported at $41.0 million in Q1 2026.
- For the quarter ending Q1 2026, Deferred Taxes rose 17199.17% year-over-year to $41.0 million; the trailing twelve-month figure through Mar 2026 stood at $44.2 million (up 259.76% YoY), and the FY2025 full-year result was $43.8 million, up 447.52% from the prior year.
- Deferred Taxes for Q1 2026 stood at $41.0 million, up from $4.1 million in the prior quarter.
- Across five years, Deferred Taxes topped out at $41.0 million in Q1 2026 and bottomed at -$15.4 million in Q3 2024.
- The 5-year median for Deferred Taxes is -$240000.0 (2025), against an average of $4.0 million.
- The widest annual swing landed in 2024, when Deferred Taxes slumped 1284.57%; it then soared 17199.17% in 2026.
- A 5-year view of Deferred Taxes shows it stood at $29.3 million in 2022, then sank by 103.81% to -$1.1 million in 2023, then plunged by 1284.57% to -$15.4 million in 2024, then jumped by 126.38% to $4.1 million in 2025, then surged by 907.81% to $41.0 million in 2026.
- The last three Deferred Taxes figures came in at $41.0 million (Q1 2026), $4.1 million (Q3 2025), and -$637000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -65.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 96.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 9.31 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 41.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.04 Mn |
| Sep 30, 2025 | 4.07 Mn |
| Jun 30, 2025 | -637,000.00 |
| Mar 31, 2025 | -240,000.00 |
| Sep 30, 2024 | -15.44 Mn |
| Jun 30, 2024 | -15.25 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Sep 30, 2023 | -1.12 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | -812,000.00 |
| Sep 30, 2022 | 29.26 Mn |
| Jun 30, 2022 | -876,000.00 |
| Mar 31, 2022 | 6.86 Mn |
| Sep 30, 2021 | 65.60 Mn |
| Jun 30, 2021 | 25.33 Mn |
| Mar 31, 2021 | 19.74 Mn |
| Dec 31, 2020 | 15.73 Mn |
| Sep 30, 2020 | 8.87 Mn |
| Jun 30, 2020 | 19.89 Mn |
| Mar 31, 2020 | 15.93 Mn |
| Dec 31, 2019 | 12.38 Mn |
| Sep 30, 2019 | 10.56 Mn |
| Jun 30, 2019 | 10.43 Mn |
| Mar 31, 2019 | 8.51 Mn |
| Dec 31, 2018 | -196.05 Mn |